190 related articles for article (PubMed ID: 35042239)
1. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study.
Joelsson J; Wästerlid T; Rosenquist R; Jakobsen LH; El-Galaly TC; Smedby KE; Eloranta S
Blood Adv; 2022 Apr; 6(8):2657-2666. PubMed ID: 35042239
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
Calip GS; Moran KM; Sweiss KI; Patel PR; Wu Z; Adimadhyam S; Lee TA; Ko NY; Quigley JG; Chiu BC
Cancer; 2019 Apr; 125(7):1143-1154. PubMed ID: 30548485
[TBL] [Abstract][Full Text] [Related]
3. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
4. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myelodysplasia and acute myeloid leukemia.
Bhatia S
Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
[TBL] [Abstract][Full Text] [Related]
6. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
Radivoyevitch T; Dean RM; Shaw BE; Brazauskas R; Tecca HR; Molenaar RJ; Battiwalla M; Savani BN; Flowers MED; Cooke KR; Hamilton BK; Kalaycio M; Maciejewski JP; Ahmed I; Akpek G; Bajel A; Buchbinder D; Cahn JY; D'Souza A; Daly A; DeFilipp Z; Ganguly S; Hamadani M; Hayashi RJ; Hematti P; Inamoto Y; Khera N; Kindwall-Keller T; Landau H; Lazarus H; Majhail NS; Marks DI; Olsson RF; Seo S; Steinberg A; William BM; Wirk B; Yared JA; Aljurf M; Abidi MH; Allewelt H; Beitinjaneh A; Cook R; Cornell RF; Fay JW; Hale G; Chakrabarty JH; Jodele S; Kasow KA; Mahindra A; Malone AK; Popat U; Rizzo JD; Schouten HC; Warwick AB; Wood WA; Sekeres MA; Litzow MR; Gale RP; Hashmi SK
Leuk Res; 2018 Nov; 74():130-136. PubMed ID: 30055822
[TBL] [Abstract][Full Text] [Related]
7. Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks.
Al-Juhaishi T; Khurana A; Shafer D
Best Pract Res Clin Haematol; 2019 Mar; 32(1):47-53. PubMed ID: 30927975
[TBL] [Abstract][Full Text] [Related]
8. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
9. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
[TBL] [Abstract][Full Text] [Related]
10. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
11. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
12. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
[TBL] [Abstract][Full Text] [Related]
13. Second malignancies following treatment in non-Hodgkin's lymphoma.
Ellis M; Lishner M
Leuk Lymphoma; 1993 Mar; 9(4-5):337-42. PubMed ID: 8348069
[TBL] [Abstract][Full Text] [Related]
14. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Scholz M; Engert A; Franklin J; Josting A; Diehl V; Hasenclever D; Loeffler M
Ann Oncol; 2011 Mar; 22(3):681-688. PubMed ID: 20720088
[TBL] [Abstract][Full Text] [Related]
15. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Koontz MZ; Horning SJ; Balise R; Greenberg PL; Rosenberg SA; Hoppe RT; Advani RH
J Clin Oncol; 2013 Feb; 31(5):592-8. PubMed ID: 23295809
[TBL] [Abstract][Full Text] [Related]
16. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.
André M; Mounier N; Leleu X; Sonet A; Brice P; Henry-Amar M; Tilly H; Coiffier B; Bosly A; Morel P; Haioun C; Gaulard P; Reyes F; Gisselbrecht C;
Blood; 2004 Feb; 103(4):1222-8. PubMed ID: 14576060
[TBL] [Abstract][Full Text] [Related]
17. Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.
Goldin LR; Kristinsson SY; Liang XS; Derolf AR; Landgren O; Björkholm M
J Clin Oncol; 2012 Jan; 30(2):179-83. PubMed ID: 22162584
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Kaplan HG; Malmgren JA; Atwood MK
BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
[TBL] [Abstract][Full Text] [Related]
19. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
20. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.
Radivoyevitch T; Sachs RK; Gale RP; Molenaar RJ; Brenner DJ; Hill BT; Kalaycio ME; Carraway HE; Mukherjee S; Sekeres MA; Maciejewski JP
Leukemia; 2016 Feb; 30(2):285-94. PubMed ID: 26460209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
